About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CER-001

Company: Cerenis Therapeutics, SA
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Completed NCT NCT01201837

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

Not yet reported Cerenis Therapeutics, SA 507 participants Est. completion 2013-03 47 sites Stand-alone

Other conditions: Acute Coronary Syndrome
View official trial listing →
Completed NCT NCT01412034

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects

Not yet reported Cerenis Therapeutics, SA 23 participants Est. completion 2014-08 9 sites Stand-alone

Other conditions: Homozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT01515241

Exploratory Study of Plaque Regression

Not yet reported Cerenis Therapeutics, SA 10 participants Est. completion 2012-05 1 site

Other conditions: Heterozygous Familial Hypercholesterolemia
View official trial listing →
Completed NCT NCT02484378

CER-001 Atherosclerosis Regression ACS Trial

Not yet reported Cerenis Therapeutics, SA 301 participants Est. completion 2016-12 35 sites Stand-alone

Other conditions: Acute Coronary Syndromes
View official trial listing →
Terminated NCT NCT02697136

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Not yet reported Cerenis Therapeutics, SA 30 participants Est. completion 2018-12-21 19 sites Stand-alone

Other conditions: Familial Hypoalphalipoproteinemia
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT01515241

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.